ribosomal protein L7a pseudogene 73Genealiases: []
Q-omics provides the consensus-scored RPL7AP73 profile across patient tissues and cancer cell-line models. RPL7AP73 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPL7AP73 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, RPL7AP73 RNA expression shows 5,560 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRP, and STAD as cancer lineages where RPL7AP73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP73 survival associations across molecular data types. RPL7AP73 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP73 RNA expression–survival associations across cancer types. High RPL7AP73 expression shows unfavorable associations in LUAD, ACC, MESO, BRCA and KICH, but favorable associations in UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPL7AP73 RNA expression.
This table summarizes RPL7AP73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP73 shows higher tumor expression in KIRP, COAD, PRAD, LIHC and THCA. The KIRP box plot shows higher RPL7AP73 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p = .001).
This table shows molecular features associated with RPL7AP73 in patient tissues and cancer cell lines. In patient samples, RPL7AP73 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
